Seleccione idioma:  
RTICC 2013
Programas RTICC
Seguimiento cientifico

The current proposal for an ISCIII-sponsored RETIC on cancer for the period 2013-2016 reflects the natural evolution of prior experiences of cooperative cancer research networks previously held in Spain on a continuous basis since 2003. In particular, an initial Network of Cancer Research Centers (Red Temática de Investigación Cooperative de Centros de Cancer, RTICCC) was established during the years 2003-2006 that encompassed 23 separate institutions research centers (126 individual groups) located in different hospitals and research centers located of 12 different autonomous regions of Spain. Since 2006, the Spanish Cancer Network switched focus from the research centers to the individual lPI-led groups and a new Red Temática de Investigación Cooperativa en Cancer, RTICC, was established that involved the cooperative work of 95 distinct, PI-led groups (85 Regular groups, and 15 clinical associate groups) distributed in institutions located in 13 different CCAA of this country. Despite its initial conception as 4 year project, the ISCIII has extended the activities and validity of the current RTICC has extended its activities for a total 6 years, until the end of 2012. The current proposal for a new RETIC on cancer is being presented by the 20-member Executive Committee of the current RTICC, in an effort to extend and improve on the quality and results yields of the research efforts of the Cancer research cooperative in our country.

It is also pertinent to mention that the Strategic Action Plan presented in this document represents a natural continuation of the Strategic Action Plans that were implemented and refined periodically in the RTICC network in response to the yearly evaluations and recommendations received during the period 2007-2012 from either ad hoc external evaluation agencies commissioned by ISCIII or from its own external Scientific Advisory Board. As many of those recommendations were geared at improving the scientific quality and international competitiveness of the RTICC network components, the current proposal reflects an emphasis on (i) the translational orientation of basic, clinical and epidemiological research tasks planned for the network as well as on (ii) the lower number, (iii) bigger size and (iv)higher scientific productivity of the groups selected to participate in this initiative. In this regard it is worth mentioning that the list of groups participating in the current proposal is composed by (i) a majority (about 80%) of RTICC groups that were consistently evaluated in the top 50% of that network and a (ii) smaller group (about 15%) of new, high quality research groups that were not previously part of RTICC as they were integrated in research structures (such as Consoliders) that were deemed incompatible with the RETICs by ISCIII (to which they have now resigned).

Work Packages
Coordinación RTICC
03/03/2017 | Otras reuniones
13/11/2016 | Otras reuniones
Unveiling changes in the landscape of patient populations in cancer early drug development.
Hierro C, Azaro A, Argilés G, Elez E, Gómez P, Carles J, Rodon J
Oncotarget  2017.  8.  14158-14172.  PMID: 27835915. 

The expanding role of immunotherapy.
Martin-Liberal J, Ochoa de Olza M, Hierro C, Gros A, Rodon J, Tabernero J
Cancer Treat Rev  2017.  74-86.  PMID: 28231560. 

The consensus molecular subtypes of colorectal cancer.
Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S
Nat Med  2015.  11.  1350-6.  PMID: 26457759. 

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
Obermannová R, Van Cutsem E, Yoshino T, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia Alfonso P, Portnoy D, Cohn A, Yamazaki K, Clingan P, Lonardi S, Kim TW, Yang L, Nasroulah F, Tabernero J
Ann Oncol  2016.  11.  2082-2090.  PMID: 27573561. 

Single-cell transcriptome conservation in cryopreserved cells and tissues.
Guillaumet-Adkins A, Rodríguez-Esteban G, Mereu E, Mendez-Lago M, Jaitin DA, Villanueva A, Vidal A, Martinez-Marti A, Felip E, Vivancos A, Keren-Shaul H, Heath S, Gut M, Amit I, Gut I, Heyn H
Genome Biol  2017.  1.  45.  PMID: 28249587. 

Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients.
Sclafani F, Chau I, Cunningham D, Lampis A, Hahne JC, Ghidini M, Lote H, Zito D, Tabernero J, Glimelius B, Cervantes A, Begum R, De Castro DG, Wilson SH, Peckitt C, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Braconi C, Valeri N
Carcinogenesis  2016.  9.  852-7.  PMID: 27381831. 

SEOM Clinical Guideline for the treatment of pancreatic cancer (2016).
Vera R, Dotor E, Feliu J, González E, Laquente B, Macarulla T, Martínez E, Maurel J, Salgado M, Manzano JL
Clin Transl Oncol  2016.  12.  1172-1178.  PMID: 27896637. 

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.
Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Wee Ma W, Reni M, Harris M, Whorf R, Liu H, Shiansong Li J, Manax V, Romano A, Lu B, Goldstein D
Br J Cancer  2016.  9.  e13.  PMID: 27657342. 

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.
Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Ma WW, Reni M, Harris M, Whorf R, Liu H, Li JS, Manax V, Romano A, Lu B, Goldstein D
Br J Cancer  2016.  2.  188-94.  PMID: 27351217. 

Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.
Duran I, Lambea J, Maroto P, González-Larriba JL, Flores L, Granados-Principal S, Graupera M, Sáez B, Vivancos A, Casanovas O
Target Oncol  2017.  1.  19-35.  PMID: 27844272. 

Ministerio de Economia y Competitividad
Red Temática Investigación Cooperativa Sanitaria
Rticc 2012
Red Temática Investigación Cooperativa en Cáncer (RTICC)
Centro de Investigación Cáncer - Campus Miguel de Unamuno - 37007 - Salamanca
(+34) 923294803 - sec.rticc[arroba]usal.es
Sobre la RTICC Programas RTICC Ofertas de empleo y Agenda Seguimiento científico
Red Temática de Investigación Cooperativa en Cáncer · © Copyright 2013 · sec.rticc[arrroba]usal.es · diseño web: detrazos